Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016154559 - PEPTIDES THAT MODULATE THE EFFECT OF THE CRMP: NEUROFIBROMIN COMPLEX ON SYNAPTIC TRANSMISSION

Publication Number WO/2016/154559
Publication Date 29.09.2016
International Application No. PCT/US2016/024266
International Filing Date 25.03.2016
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
A61K 47/645
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Applicants
  • INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION [US]/[US]
Inventors
  • KHANNA, Rajesh
Agents
  • CHO, Taewoo
Priority Data
62/138,20325.03.2015US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PEPTIDES THAT MODULATE THE EFFECT OF THE CRMP: NEUROFIBROMIN COMPLEX ON SYNAPTIC TRANSMISSION
(FR) PEPTIDES QUI MODULENT L'EFFET DU COMPLEXE CRMP:NEUROFIBROMINE SUR LA TRANSMISSION SYNAPTIQUE
Abstract
(EN)
The present disclosure relates generally to materials and methods for studying and treating neurofibromatosis type 1 (NF1) by modulating the interaction of CRMP-2 and neurofibromin. Some embodiments relates to newly synthesized polypeptides or a pharmaceutically acceptable salt thereof. Other embodiments relate to methods of treating a patient by providing at least one polypeptide. Another embodiment relates to a kit comprising at least one polypeptide.
(FR)
La présente invention concerne d'une manière générale des matériaux et des procédés permettant d'étudier et de traiter la neurofibromatose de type 1 (NF1) par modulation de l'interaction de CRMP-2 et de la neurofibromine. Certains modes de réalisation de la présente invention concernent de nouveaux polypeptides synthétisés ou un sel pharmaceutiquement acceptable de ceux-ci. D'autres modes de réalisation se rapportent à des procédés de traitement d'un patient en utilisant au moins un polypeptide. Un autre mode de réalisation concerne un kit comprenant au moins un polypeptide.
Also published as
Latest bibliographic data on file with the International Bureau